Genmab (GMAB) denied Saturday allegations of misappropriating trade secrets related to the use of disaccharides in antibody-drug conjugates in a lawsuit filed by AbbVie (ABBV).
The company said it would defend itself against AbbVie's complaint, which also named ProfoundBio and former AbbVie employees as defendants. Genmab acquired ProfoundBio in May 2024.
AbbVie is seeking damages and injunctions but is not pursuing patent enforcement, Genmab said.
Genmab said its collaboration with AbbVie on the epcoritamab program will not be affected by the lawsuit.
AbbVie did not immediately respond to MT Newswires' request for comment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。